AbCellera Biologics (ABCL) Times Interest Earned (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Times Interest Earned came in at -$15.6 in Q1 2026, down 2970.01% on a QoQ basis from -$0.51 in Q4 2025.
AbCellera Biologics (ABCL) Times Interest Earned (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Times Interest Earned data on file, last reported at -$15.6 in Q1 2026.
- Quarterly Times Interest Earned changed N/A year-over-year to -$15.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.51 (changed N/A YoY) and the FY2025 annual result came in at -$3.86, up 38.78% from the prior year.
- Times Interest Earned eased to -$15.6 in Q1 2026, from -$0.51 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $55.67 in Q1 2022 to a low of -$17.73 in Q4 2023.
- A 5-year average of -$1.42 and a median of -$2.82 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 224.17% — and 2023, when it sank 529.49%.
- Tracing ABCL's Times Interest Earned over 5 years: stood at -$2.82 in 2022, then slumped by 529.49% to -$17.73 in 2023, then soared by 91.78% to -$1.46 in 2024, then surged by 65.13% to -$0.51 in 2025, then tumbled by 2970.01% to -$15.6 in 2026.
- The last three Times Interest Earned figures came in at -$15.6 (Q1 2026), -$0.51 (Q4 2025), and -$1.46 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -18.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.82 |
| Mar 31, 2026 | -15.60 |
| Dec 31, 2025 | -0.51 |
| Dec 31, 2024 | -1.46 |
| Dec 31, 2023 | -17.73 |
| Sep 30, 2023 | -12.77 |
| Jun 30, 2023 | -11.96 |
| Mar 31, 2023 | -15.30 |
| Dec 31, 2022 | -2.82 |
| Sep 30, 2022 | 8.90 |
| Jun 30, 2022 | -2.08 |
| Mar 31, 2022 | 55.67 |
| Dec 31, 2021 | 815.53 |
| Sep 30, 2021 | -7.17 |
| Jun 30, 2021 | -2.02 |
| Mar 31, 2021 | 26.79 |
| Dec 31, 2020 | 169.42 |